Managing Patients with ER-positive/HER2-negative MBC
| Current and Future Oral SERD Strategies in the Management of ER-Positive/HER2-Negative MBC: Analyzing the Clinical Data | |||
 |
|||
|
|||
|
|||
| Did you know that as MBC patients get treated with multiple lines of ET, the percentage of patients who develop an ESR1 mutation increases? | |||
|
|||
|
